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We present a transmission dynamic model that can
assess the epidemiologic consequences and cost-effec-
tiveness of alternative strategies of administering a prophy-
lactic quadrivalent (types 6/11/16/18) human papillo-
mavirus (HPV) vaccine in a setting of organized cervical
cancer screening in the United States. Compared with cur-
rent practice, vaccinating girls before the age of 12 years
would reduce the incidence of genital warts (83%) and cer-
vical cancer (78%) due to HPV 6/11/16/18. The incremen-
tal cost-effectiveness ratio (ICER) of augmenting this
strategy with a temporary catch-up program for 12- to 24-
year-olds was US $4,666 per quality-adjusted life year
(QALY) gained. Relative to other commonly accepted
healthcare programs, vaccinating girls and women appears
cost-effective. Including men and boys in the program was
the most effective strategy, reducing the incidence of geni-
tal warts, cervical intraepithelial neoplasia, and cervical
cancer by 97%, 91%, and 91%, respectively. The ICER of
this strategy was $45,056 per QALY.
H
uman papillomavirus (HPV) causes cervical intraep-
ithelial neoplasia (CIN); cervical, anal, penile, vagi-
nal, vulvar, and head/neck cancers; anogenital warts; and
recurrent respiratory papillomatoses, resulting in disease
and death in both women and men (1). Cervical cancer
incidence and deaths have substantially decreased in coun-
tries with organized cervical cancer screening programs
(2). However, despite this success, cervical cancer is the
second most common malignancy among women and a
leading cause of cancer death worldwide, with an estimat-
ed 493,000 new cases and 274,000 deaths in 2002 (3).
In the United States, public health authorities recom-
mend that girls and women 11–26 years of age be vaccinat-
ed with the newly licensed quadrivalent HPV vaccine,
Gardasil (Merck & Co., Inc., Whitehouse Station, NJ,
USA), to prevent cervical cancer, precancerous and low-
grade lesions, and genital warts caused by HPV types 6, 11,
16, or 18. Policymakers will need information on the epi-
demiologic and economic impact of HPV vaccination to
formulate guidelines (4,5). Cohort models provided some
of this information but could not fully assess the impact of
HPV vaccination (6). In particular, vaccination will not
only directly protect through vaccine-derived immunity but
also indirectly through herd immunity. To account for these
direct and indirect effects, a population dynamic model is
necessary (7). Moreover, a dynamic model can evaluate a
broader range of vaccination strategies (e.g., vaccination of
boys and men). A few dynamic models exists (6,8), but
only 1 has examined the cost-effectiveness of bivalent HPV
(16/18) vaccination strategies (9).
We developed a dynamic model to assess the epidemi-
ologic consequences and cost-effectiveness of alternative
quadrivalent HPV (6/11/16/18) vaccination strategies. An
online Supplementary Appendix (available from www.
cdc.gov/ncidod/EID/13/1/28-app.htm) describes in detail
the model structure and inputs. Specifically, we examined
2 questions: What is the potential impact of a quadrivalent
HPV vaccine on HPV infection and disease in the US pop-
ulation? What is the cost-effectiveness of a quadrivalent
HPV vaccine program when added to the current standard
of care from the perspective of the US healthcare system?
Methods
Screening and Vaccination Strategies
We assumed that the vaccine will be combined with
current screening and HPV disease treatment practices. We
defined the reference vaccination strategy to be routine
HPV vaccination of girls by age 12 (F12-only) (10). We
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*Merck Research Laboratories, North Wales, Pennsylvania, USAalso examined the following strategies: 1) routine vaccina-
tion of girls and boys by age 12 (F&M12), 2) routine vac-
cination of girls by age 12 and catch-up female vaccination
for those ages 12–24 (F12-only+CUF-only), 3) routine
vaccination of boys and girls by age 12 years and catch-up
female vaccination for those ages 12–24 years
(F&M12+CUF-only), and 4) routine vaccination of boys
and girls by age 12 and catch-up female and male vaccina-
tion for those ages 12–24 (F&M12+CUF&M).
Dynamic Model Structure
Our dynamic model has demographic and epidemio-
logic components ([11], Appendix). The demographic
model defines the demographic characteristics of the pop-
ulation being simulated and describes how persons enter,
age, and exit various categories. The heterosexually mix-
ing population is divided into 17 age groups. Each age
group consists of persons with low, medium, or high sexu-
al activity.
Twelve-year-old persons enter the population at a gen-
der-specific and sexual activity–specific rate. Persons then
move between successive age groups at an age- and gen-
der-specific rate per year (11). Persons exit the model upon
death at an age- and gender-specific per capita death rate
per year. Cervical cancer patients have an additional age-
and stage-dependent death rate. Patients with CIN or gen-
ital warts do not face an additional risk for death.
The epidemiologic model simulates HPV transmis-
sion and the occurrence of CIN, cervical cancer, and exter-
nal genital warts in this age-structured population. The
acquisition of infection and progression of persons from
infection to disease follow a similar natural history struc-
ture, as assumed in previous models for HPV 16/18 (6).
We also incorporated HPV 6/11 infection and genital
warts, and grouped infections into HPV 16/18, HPV 6/11,
or HPV 6/11/16/18. We divided the population into distinct
epidemiologic categories, according to the person’s status
with respect to infection, disease, screening, and treatment
(Appendix, Figure 1A–B).
Parameters for Estimates and Sources
Acomprehensive search of the literature was conduct-
ed to obtain baseline values for the parameters of the
model (Appendix Tables A1–A3). We used age-stratified
data to estimate cytology screening rates (12–14).
Estimates of cytology screening sensitivities and specifici-
ties were based on published studies (15,16).
The degree of protection from the vaccine (the propor-
tion of challenges against which a recipient is protected)
against incident infection (HPV 6/11 or 16/18) was 90%;
against associated disease the degree of protection was
100% (17,18). We assumed the duration of protection was
lifelong for the reference case (6) and examined a 10-year
duration in sensitivity analyses. We assumed the natural
course of disease was unaltered following vaccine failure
or loss of vaccine-induced immunity. Because Gardasil is
a prophylactic vaccine, we did not include any therapeutic
benefits to recipients already infected with the vaccine
types. We assumed that up to 70% of 12-year-olds received
a 3-dose vaccine (6). Coverage increased linearly from 0%
up to 70% during the first 5 years of the program (e.g.,
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Figure 1. A simplified schematic diagram of human papillomavirus
(HPV) infection and disease state transitions, lifetime duration of
infection-derived immunity, unvaccinated compartments. A)
Persons enter into the susceptible (X) compartment and leave all
compartments at sex- and age-specific rate. A susceptible host
may be infected by either or both HPV types. A host infected with
a given type can also be infected with the other type and move into
compartment (Y12). An infected person can clear infection with 1
type and can become immune to that type (Zh) and be infected
with the other type (Uh). Infection with and clearance of all types
results in lifetime immunity. B) Cervical intraepithelial neoplasia
(CIN) develops in females and progresses though several histo-
logic states: infected with a normal cervix; CIN 1; CIN 2; CIN 3;
localized, regional, and distant cervical cancer. CIN can regress to
normal with or without infection. Genital warts can develop and
clear in those infected with HPV 6/11.14% in year 1, 28% in year 2) and remained at 70% there-
after. Vaccine coverage for the catch-up program increased
linearly from 0% up to 50% during the first 5 years (e.g.,
10% in year 1, 28% of unvaccinated in year 2), and the
program was eliminated after year 5.
We assumed the cost of the HPV vaccine for 3 doses
and administration would be US $360 (range $300–$500),
consistent with previous analyses (6). All costs were
updated to 2005 US dollars. Costs and quality-adjusted life
years (QALY) were discounted at 3%.
Simulation Method
We assessed the epidemiologic impact and cost-effec-
tiveness of each vaccination strategy over a planning hori-
zon of 100 years. We solved the model for the
prevaccination steady-state values of the variables and
used them as initial values for the vaccination model. Next,
we solved the model for the entire time path of the vari-
ables until the system approached a steady-state.
Validation Analyses
We established the face validity of the model by con-
sulting with experts on assumptions regarding the natural
history of HPV infection and disease (19). The accompa-
nying online Supplementary Appendix allows for further
critical review of the model assumptions and provides the
mathematical equations necessary to reproduce the results
(19,20). The predictive validity of the model was evaluat-
ed by comparing model results with epidemiologic data
from unscreened and screened populations in the United
States (2,21–23).
Sensitivity Analyses
Because of the large number of equations and inputs,
we used a smaller version of the model to determine the
most influential inputs. Based on these results, 1-way sen-
sitivity analyses using the full model were performed on
vaccine parameters (duration, degree, coverage, cost, tar-
get age), quality-of-life weights, discounting, and duration
of natural immunity. We also conducted a multivariate sen-
sitivity analysis that examined a pessimistic scenario (i.e.,
duration of protection = 10 years; vaccine coverage =
50%; health utility for genital warts; CIN 1, 2, 3, and car-
cinoma in situ (CIS) = 0.97; degree of protection against
infection = 75%; and degree of protection against HPV-
related disease = 85%). We also examined the role of herd
immunity.
Results
Model Validation
Model predictions generally fell within the range of
values reported in the literature. Overall, HPV 6/11 steady-
state prevalence among females was 0.7%, which is simi-
lar to that reported by Giuliano et al. (24) for15- to 59-
year-old women. The predicted age-specific HPV
prevalence curve had a shape and magnitude at peak simi-
lar to data reported in the literature (24–28) (Figure 2).
Without screening, the predicted HPV 16/18-attributable
cervical cancer incidence curve had a shape and magnitude
at peak (39 per 100,000 women-years for ages 45–50) sim-
ilar to those estimated from unscreened US populations
(22,29). The model predicted that 20% of all cervical can-
cer cases occurred among women who were never
screened, similar to what has been observed in US popula-
tions (30). Also, the cervical cancer incidence curve (HPV
16/18 attributable) had a shape and magnitude at peak (8.3
per 100,000 women-years for ages 30−39 years) similar to
that observed among recent cohorts of US women (23).
However, the model predicted lower cervical cancer inci-
dence among older cohorts. This approximation may be
reasonable given that future cohorts of older women are
expected to have lower cervical cancer incidence than
women currently in older age groups (fewer women
missed screening at younger ages among more recent
cohorts [13,14]). Finally, with screening, the age-specific
incidence curves for CIN and genital warts generally had
shapes and magnitudes at peak similar to data reported in
the literature (21,31).
Epidemiologic Impact of HPV 
Vaccination Strategies (Reference Case)
Steady-state HPV prevalence rates were higher for
boys or men than for girls or women across all age groups
(Figure 2). Overall, HPV 16/18 steady-state prevalence
among girls and women >12 years of age (2.4%) was high-
er than that for boys or men (1.7%) and increased with
level of sexual activity (data not shown). For both sexes,
prevalence increased with age, reached a peak in the 20- to
24-year age group and continuously declined thereafter.
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Figure 2. Human papillomavirus (HPV) prevalence by sex and age
group, as predicted by the model and reported in selected studies
from North America. HPV high risk includes types 16, 18, 31, 33,
35, 39, 45, 51, 52, 56, 58, 59, 68, 73, and 82. Across all strategies, the effect of the vaccine was to
steadily reduce CIN 2/3 incidence until the system
approached a steady state (Figure 3). The largest reduction
was accomplished by adopting F&M12+CUF&M.
Cervical cancer curves shared the same qualitative features
of those of CIN 2/3 (Figure 4). However, because cervical
cancer progresses slowly, the effect of vaccination on the
reduction in incidence and cancer deaths was more gradual
compared with that for CIN 2/3 (Figures 3 and 4).
For genital warts, the reduction occurred sooner
(Figure 5A and 5B). Female-only vaccination strategies
were effective in reducing genital warts incidence among
adolescent girls and women (Figure 5B) and were also
effective in reducing the incidence of genital warts among
males, but were not as effective as strategies that included
male vaccination (Figure 5A).
F&M12+CUF&M had the most effect on the number
of cases of genital warts, CIN, and cervical cancer.
Compared with screening only, this strategy substantially
reduced the long-run, overall number of genital warts
(97%), CIN 2/3 (91%), and cervical cancer cases (91%)
among adolescent girls and women.
Economic Impact of HPV Vaccination 
Strategies (Reference Case)
F&M12 was less effective and more costly (dominat-
ed) than F12-only+CUF-only (Table 1). The incremental
cost-effectiveness ratio (ICER) of F12-only+CUF-only
was US $4,666/QALY, and the most effective strategy
(F&M12+CUF&M) had an ICER of $45,056/QALY.
Sensitivity Analyses
With 10 years’ duration of protection, vaccination
reduced disease incidence steadily until ≈10–15 years after
vaccination, when the loss of immunity among vaccinated
persons and increased numbers of unvaccinated persons
reversed these trends and caused the incidence to rise
(Figure 6). The rise in incidence continued until years
20–30, after which, it fell steadily until a steady state was
approached. The timing and magnitude of the reduction
and resurgence in incidence depended on the strategy. The
largest reduction and lowest rebound were accomplished
by using F&M12+CUF&M. If the duration of protection
was only 10 years, long-term reductions in the annual
number of cases of genital warts among males, CIN 2/3,
and cervical cancer would be 36%, 25%, and 28%, respec-
tively. In addition, ICERs increased by changing the dura-
tion of protection from lifelong to 10 years (Table 2).
The long-term cervical cancer incidence and ICER
were not very sensitive to changes in the degree of vaccine
protection against infection and disease. However, the
results were sensitive to varying vaccination coverage. For
example, the impact of vaccination on cervical cancer was
lower when coverage was 50% compared with 90%
(Figure 7). Lower coverage made vaccinating adolescent
boys and men more cost-effective (Table 2). Increasing
vaccination cost and quality of life weights increased
ICERs.
Lower discount rates resulted in higher costs and
QALY for each vaccination strategy. Discounting both
costs and QALY at 1% decreased ICERs of the nondomi-
nated strategies: F12-only+CUF-only had an ICER of
$448/QALY, whereas the ICER of F&M12+CUF&M was
$28,614 /QALY. With a 5% discount rate, ICERs of these
2 strategies increased to $10,138/QALY and $64,413/
QALY, respectively. HPV prevalence and burden of HPV-
related diseases increased with shorter duration of natural
immunity. A higher background rate of disease made the
impact of vaccination look more favorable. For example,
with 10-year duration of natural immunity, F12-only+
CUF-only was cost-saving, whereas the ICER of F&M12+
CUF&M was $11,567/QALY.
When the effects of herd immunity and benefits of
prevention of HPV 6/11 were removed, the ICER of F12-
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Figure 3. Incidence of cervical intraepithelial neoplasia (CIN) 2/3
due to human papillomavirus 6/11/16/18 infection among girls and
women >12 years of age, by vaccination strategy. 
Figure 4. Incidence of cervical cancer due to human papillo-
mavirus 16/18 infection among girls and women >12 years of age,
by vaccination strategy.only increased to $21,404. If one assumes a pessimistic
scenario, the ICER of the F12-only+CUF-only strategy
increased from $4,446/QALY to $29,053/QALY and the
ICER of the F&M12+CUF&M increased from $45,056/
QALY to $124,063/QALY.
Because vaccination coverage rates are expected to be
lower among older age groups, we assumed a rate of 50%
among 15- and 18-year-olds. With these rates, F12-
only+CUF-only had an ICER of $8,357/QALY compared
with delaying age of vaccination to 18 years (Table 3).
ICERs of vaccinating by age 12 years increased when
coverage rates among persons of ages 15 and 18 years
were higher. Increasing the target age of vaccination
decreased the benefits of vaccination (Figure 8, Table 3).
Finally, to estimate the additional value of preventing
HPV 6/11 infection, we conducted an analysis in which we
assumed that persons had no protection against HPV 6/11
infection and related disease. The results of this analysis
showed that ICERs of F12-only+CUF-only and F&M12+
CUF&M increased to $11,254/QALY and $74,151/QALY,
respectively.
Discussion
We developed an integrated transmission dynamic
model and economic evaluation to inform HPV vaccine
policy recommendations and decisions. We gained valu-
able insights by comparing various vaccination strategies.
In general, the results suggest that a quadrivalent HPVvac-
cine program that targets female adolescents and women,
ages 12–24 years, can be cost-effective ($4,666/QALY)
when compared with other commonly accepted medical
interventions (32). These findings are consistent with other
cohort-based cost-effectiveness analyses, which generally
show that vaccination of 12-year-old girls can be cost-
effective but also illustrate the substantial herd immunity
benefits provided by vaccination.
Some results from this model were qualitatively simi-
lar to the results of other studies with respect to the finding
that male vaccination was more attractive the lower the
coverage among girls and women (9). However, the results
of our base case differ qualitatively from that of Taira et al.
(9) regarding the conclusion that vaccinating males and
females would not be cost-effective. This difference in
results may be explained as follows. First, unlike Taira et
al., we accounted for the additional benefits conferred by
protecting against HPV 6/11 infection among adolescent
boys and girls, women, and men. Second, we were able to
account for all the benefits and costs of vaccination real-
ized by both those vaccinated and not vaccinated. Third,
we assumed lower weights for the quality of life of women
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Figure 5. A) Incidence of genital warts due to human papillo-
mavirus (HPV) 6/11 infection among boys and men >12 years of
age by strategy. B) Incidence of genital warts due to HPV 6/11
infection among girls and women >12 years, of age by strategy.with CIN. However, the comparison is not perfect because
our model tracks a population, whereas the model of Taira
et al. follows a cohort. Hence, the composition of the
numerators and denominators used in the ICERs differs
between models. Finally, other methodologic differences
occur between the 2 approaches that may explain the dif-
ferences in results. For example, Taira et al. used steady-
state values of HPV infection rates as inputs in their cost-
effectiveness model, whereas we measured all outcomes
over time, thereby capturing all the effects of transient
dynamics generated from widespread vaccination. We also
note that the results of the sensitivity analysis, when the
effects of herd immunity and benefits of prevention of
HPV 6/11 were removed, suggest that the ICER of the
female vaccination strategy was $21,404/QALY, which is
close to the value of $22,755/QALY reported in another
study by Sanders and Taira (33).
An important finding from this analysis was that
catch-up vaccination can substantially reduce disease in
the short term. As a result, the female and male strategy
that did not include a catch-up program was less effective
and more costly.
One of the influential inputs was vaccine coverage. As
female coverage rates decreased, male vaccination became
more efficient. Another influential input in the analysis
was the quality-of-life weights. The less HPV disease
affected quality of life, the more the ICERs increased.
Duration of protection was also an influential param-
eter. Decreasing duration of vaccine protection to 10 years
increased ICERs. However, the impact of this decrease
may be mitigated by introducing a booster program. Area-
sonable approximation for how this program might fare
would be to look at the sensitivity of ICERs to changes in
vaccination cost. Thus, increasing the cost of the HPV vac-
cine series to $500 increased ICERs (Table 2). However,
all nondominated (i.e., either are less costly or have lower
ICERs than more effective strategies) female strategies
remained cost-effective. Another influential parameter was
the age vaccination was begun. Earlier vaccination result-
ed in greater benefits. F&M12+CUF&M was cost-effec-
tive ($42,697/QALY). However, vaccination by age 12
became less efficient, the higher the vaccination coverage
was among older age groups.
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Figure 6. Sensitivity analysis. A) Incidence of genital warts due to
human papillomavirus (HPV) 6/11 infection among boys and men
>12 years of age, by strategy, 10 years’ duration of protection. B)
Incidence of genital warts due to (HPV 6/11 infection among girls
and women >12 years of age by strategy, 10 years’ duration of
protection.Vaccination shifted the age of infection and disease to
older age groups. For example, the age of peak cervical
cancer incidence increased after introducing vaccination.
The upward shifting of age of infection is a common fea-
ture of many vaccination programs (11).
We believe our modeling approach has several
strengths. First, we did extensive validation with existing
data. The model is also flexible enough to incorporate bet-
ter data as they become available. Second, this model
accounts for actual screening practices in the United
States. Third, because output from this model is population
based, the comparison with national registry data is better
aligned than comparison of cohort model output with pop-
ulation data (6). Finally, all equations and inputs for this
model are available to facilitate replication of findings and
independent review of the model.
Several enhancements and extensions are desired.
First, more relevant data on the natural history of type-spe-
cific HPV infection and disease (e.g., HPV transmission
probability per sexual contact) are needed. Also, given the
influence utility weights have on ICERs, more studies are
needed to collect health utilities data on HPVdisease states.
Second, we modeled only 4 HPV types and their asso-
ciated diseases and assumed that HPV types have inde-
pendent natural histories with no interaction among them.
If cross-immunity exists between HPV types, a vaccine
that reduces the prevalence of 1 type may promote the
prevalence of other types through a process of competitive
release. If, however, current or prior infection with 1 HPV
type facilitates concurrent or subsequent infection with
another HPV type, or if the vaccine provides cross-protec-
tion against other types, HPV vaccination could have the
additional benefit of reducing the prevalence of HPV
infection of types not covered by the vaccine (34). The evi-
dence on interaction among HPV types to date is mixed
and inconclusive (35–39).
Third, we modeled neither coinfection after disease
developed in a person nor the coexistence of CIN lesions
due to multiple HPV types in the cervix. By accounting for
all the cost of vaccinating persons with undetected disease
and no benefits for them as a result of the protection
against the type that did not cause the disease, our results
are biased against the catch-up program.
Fourth, the model assumed that all persons have equal
access to healthcare, be it vaccination, screening, or treat-
ment. However, this assumption may not be realistic and
may overestimate the benefits of vaccination if women
who have limited access to screening are also less likely to
get vaccinated. Further studies are required to determine
whether those who do not get vaccinated are also likely not
to get screened.
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Figure 7. Sensitivity analysis. A) Incidence of cervical cancer due
to human papillomavirus (HPV) 16/18 infection among girls and
women >12 years of age with 50% coverage. B) Incidence of cer-
vical cancer due to HPV 16/18 infection among girls and women
>12 years of age with 90% coverage.Fifth, the current version of the model focused on het-
erosexual transmission of HPV and did not incorporate
transmission between homosexual and heterosexual per-
sons. Sixth, the scope of the model has been limited to cer-
vical diseases and genital warts. HPV infection has also
been associated with recurrent respiratory papillomatoses
and cancers of the anus, penis, vagina, vulva, and head and
neck. As evidence becomes available, the scope of the
model will be broadened to incorporate the potential
effects of vaccination on these other HPV conditions.
Including these diseases in the model would render more
favorable ICERs for vaccination.
Seventh, we did not include death and productivity
costs (lost wages), as was done in other analyses (40).
Including these costs would further reduce ICERs. 
Finally, we did not consider vaccination strategies that
include infants or mid-adults because current data avail-
able on vaccine safety and efficacy are limited to ages
9–26 years (18). As data for these other age groups become
available, the model can examine these strategies.
In summary, the results from this model suggest that
in a setting of organized cervical cancer screening, a pro-
phylactic quadrivalent HPV (16/18/6/11) vaccine can 1)
substantially reduce genital warts, CIN, and cervical can-
cer, 2) improve quality of life and survival, 3) be cost-
effective (across a reasonably wide range of assumptions)
when administered to girls before age 12 years (with or
without a catch-up program), and 4) have a cost-effective-
ness ratio near or below (depending on the underlying
assumptions of the model) that of several other recom-
mended vaccines, when implemented as a strategy that
combines vaccination of both girls and boys before age 12
with a 12–24 years of age catch-up program.
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Appendix1
Demographic Model
The demographic model stratifies the population by gender
and 17 age groups (12–14, 15–17, 18–19, 20–24, 25–29, 30–34,
35–39, 40–44, 45–49, 50–54, 55–59, 60–64, 65–69, 70–74,
75–79, 80–84, and >85 years). This age grouping permits age-
specific inputs for patterns of sexual activity and cervical cancer
screening and allows for age-specific outputs such as rates of cer-
vical human papillomavirus (HPV) disease among girls and
women, and genital warts among both males and females. Similar
age groupings have been used by other sexually transmitted dis-
ease models (1,2). We further stratified each age group into 3 sex-
ual activity groups (high, medium, low). We defined sexual
activity according to the rates of sex partner change per year: low
(0–1 per year), medium (2–4 per year), and high (>5 per year).
The number and the initial distribution of new entrants into the
population by each gender were chosen to satisfy the Lotka char-
acteristic equation with zero population growth (3). This allowed
for variation in results across strategies to primarily be due to epi-
demiologic and program model features and not to changes in the
demographic characteristics of the population over time (3).
The model starts with 12-year-olds entering the population
at a gender-specific and sexual activity–specific rate, and trans-
fers persons between successive age groups at an age- and gen-
der-specific rate per year. The transfer rate depends on the rate of
population growth, age- and gender-specific per capita mortality
rate, and the number of years within an age group (3). We
assumed equilibrium in the age distribution with zero population
growth.
We set the population size in the model to 100,000 persons
divided equally between females and males. Death rates for
males and for females without cervical cancer were obtained
from Vital Statistics data on gender- and age-specific mortality
rates across all races for 2002 (4). Death rates among adolescent
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1Refer to the Appendix References for citations in this Appendix.girls and women with cervical cancer were obtained from
Surveillance Epidemiology and End Results (SEER) Program
data for 1997–2002 (5). Other demographic data were obtained
from US Vital Statistics and the 2000 Census (4,6).
Epidemiologic Model
The epidemiologic model simulates HPV infection and
occurrence of HPV disease (cervical intraepithelial neoplasia
[CIN], cervical cancer, and genital warts) in the population. The
acquisition of infection and progression from infection to disease
follow a similar natural history structure, as assumed in previous
models for HPV 16 and 18 (7). Building on these previous mod-
els, we also incorporated HPV 6 and 11 infection and genital
warts and modeled infection by using 3 groups of HPV types
(HPV 16/18, HPV 6/11, or HPV 6/11/16/18).
To simulate the occurrence of CIN, genital warts, and cervi-
cal cancer among those infected with HPV, we divided the popu-
lation into distinct epidemiologic categories, according to the
population’s susceptibility to infection or the population’s status
with respect to infection, disease, screening, and treatment. These
categories were similar to what has previously been defined in
other models (7). The following, along with Figure 1, describes
the movement of the population through these categories.
HPV Infection: Acquisition and Transmission
The epidemiologic model begins with 12-year-olds entering
into the susceptible category X. Susceptible persons acquire HPV
infection with a given type (HPV 16/18 infected only, HPV 6/11
infected only, or HPV 6/11 and HPV 16/18 infected) at a rate
dependent upon gender, sexual activity group, age, and time. The
rate at which persons of a given gender, sexual activity group,
and age class at a given time acquire infection with a certain type
(per capita force of infection) depends on the number of sexual
partnerships and how these persons form partnerships with per-
sons of the opposite sex, the fraction of infected sex partners, and
the transmission probability per partnership. The formation of
sexual partnerships is governed by a conditional probability sex-
ual mixing matrix. Each cell in the mixing matrix represents the
probability of a person of a given gender, sexual activity group,
and age class having a sexual activity group, age-class specific
partner from the opposite gender. In generating the mixing
matrix, we used 2 parameters to depict the degree of mixing
between age and sexual activity groups. This strategy allowed us
to represent a wide range of mixing patterns in the matrix, from
fully assortative (as for persons with like persons when parame-
ter is zero) to proportionate (random partners when parameter is
1) mixing (1,2,8,9). The baseline parameter values for the rate of
sexual partner change, stratified by gender, sexual activity, and
age, were calculated by using data from the National Health and
Social Life Survey (10) and methods outlined in Garnett and
Anderson (2) (Appendix Table 1).
Once HPV transmission occurs, susceptible persons enter
the category of infected persons, Y. Persons leave this category
when the infectious period for HPV ends and enter the category
of recovered persons with a fixed duration of immunity, Z. In the
base case, we assumed that duration of natural immunity is life-
long. Unvaccinated infected persons clear infection at a type-spe-
cific per capita rate. Persons in the immune (Z) category who are
susceptible to only 1 type can be infected with that type and move
to another infected/immune category, U.
A fraction of susceptible persons are vaccinated and move
into the vaccination category V. The movement of those vaccinat-
ed through the model is similar to the movement of those unvac-
cinated, shown in Figure 1A. The remaining fraction of persons
who are not vaccinated remains in the susceptible category X.
The vaccine-induced immunity of those in the vaccinated catego-
ry may wane over time. As a result, persons can eventually move
to the susceptible category S at an age- and gender-dependent
rate. We assumed that when a person loses vaccine-derived
immunity, he or she becomes susceptible to infection with any of
the types. In the base case, the duration of vaccine-derived immu-
nity is assumed to be lifelong. Vaccinated persons can also expe-
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tious persons, W, at a per capita rate that depends on the degree
of protection offered by the vaccine. Vaccinated persons can
recover from an HPVinfection at an age- and gender-specific rate
by a factor that is different from the recovery rate for unvaccinat-
ed infected persons. Vaccinated persons then move to a category
with fixed duration of immunity, Q. Persons in this category who
are susceptible to 1 type can be infected with that type and move
to another vaccinated infected/immune category, P.
No epidemiologic studies have estimated the probability of
HPV infection transmission per partnership and by type. We
assumed that this probability is higher for transmission from
males to females (0.8) than that for transmission from females to
males (0.7) (12–15). Using data on participants in the placebo
arm of Merck’s HPV vaccine clinical trials, we estimated mean
duration of HPV infection before progression to CIN, or regres-
sion, at 1.2 years for HPV 16/18 and 0.7 years for HPV 6/11 (R.
Insinga, unpub. data).
CIN, Cervical Cancer, and Genital Warts
CIN develops in infected girls and women at a specified rate
and moves to the HPV disease categories of the model (Figure
1B). Several categories represent the true histologic health status
of a woman: CIN grade 1 (CIN 1), CIN grade 2 (CIN 2), CIN
grade 3 (CIN 3), localized cervical cancer (LCC), regional cervi-
cal cancer (RCC), distant cervical cancer (DCC), and cervical
cancer survivors who are free from cancer. Women with CIN and
cancer were further classified into undetected, detected, or treat-
ed categories. Two additional absorbing categories are for women
who are no longer at risk for cervical cancer (16). These include
the following: 1) women who have had a benign hysterectomy
for reasons other than cervical cancer (at an age-specific rate) and
2) women treated and cured for cervical cancer. Finally, infection
with the low-risk type can result in genital warts in females and
males and move to the genital warts category, GW (17). We
assumed women with benign hysterectomies can be infected and
are at risk for genital warts (18). Women and men recovering
from genital warts move to category Z.
We assumed all progression and regression rates to HPVand
cancer states to be independent of age (19–23). Annual transition
rates from HPV infection to clinically detectable CIN were cal-
culated from studies by Winer et al. (17) and Insinga (R. Insinga,
unpub. data). Several published reports were also used to esti-
mate annual rates of CIN regression and progression to cervical
cancer (24–31) (Merck, unpub. data). Incidence and regression
rates for genital warts were obtained from Winer et al. (17)
(Appendix Table 2). Hysterectomy rates; cervical cancer screen-
ing coverage, sensitivity, and specificity; and treatment efficacy
were derived from several published studies (32–40) (Appendix
Table 3).
Economic Parameters
All model costs were updated to 2005 US dollars by using
the medical care component of the Consumer Price Index (41).
The direct medical costs for screening and treatment for CIN,
genital warts, and cervical cancer were based on administrative
claims data and other sources (42–44). We measured the cost of
cytology screening per unit time as the product of the cost per
test, the test compliance rate, the frequency of administering the
test per unit time, and the size of the unidentified population that
is eligible for screening. We estimated the cost of following up on
false-positive results of the cytology test as a function of the
specificities of the cytology test and colposcopy procedure and
the costs of colposcopy and biopsy. The cost of the HPV vaccine
for 3 doses was assumed to be $360, which was consistent with
HPV vaccination costs used in previous cost-effectiveness analy-
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were not included in the analyses (45).
Quality adjusted life years (QALYs) were measured by
weighting survival time by the quality-of-life adjustment weights
associated with each health state and integrating the sum of
adjusted time in all these health states over the planning horizon.
We measured survival time as the total number of years spent
alive by the active population during a given period. The health
utility values used to estimate QALYs were derived from various
sources (46–48). Health utility values for diagnosed invasive can-
cer states were estimated by Myers et al. (47) at 0.76 for localized
cancer and 0.67 for regional cancer; these values were derived
from Gold et al. at 0.48 for distant cancer (46). We assumed that
the quality of life for cervical cancer survivors after successful
treatment would continue to be lower (0.76) than that of healthy
women (49,50). Diagnosed and treated CIN 1 and CIN 2/3 states
were assumed to have quality weights of 0.91 and 0.87, respec-
tively (47,48). We assumed the quality weight for genital warts to
be 0.91 (47) (Appendix Table 4).
Undiagnosed and asymptomatic HPV, CIN, and cancer
states and successfully treated CIN states were assumed to have
a quality-of-life weight similar to those of persons without these
conditions. Gender- and age-specific quality weights for non-
HPV disease states were also derived from Gold et al. (46). Time
in these states was multiplied by the age- and gender-specific
weights to reflect the variation of quality of life by age and gen-
der groups. We assumed that quality of life did not vary by
sexual activity groups. Finally, all costs and effects were dis-
counted to present value at a rate of 3%.
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